Haitao Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haitao Zhao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Danni Ai
Beijing Institute of Technology
1 shared publication Guangbing Li
Liver Transplantation Center and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
1 shared publicationHanchun Huang
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication- Hanping Wang
Department of Pulmonary and Critical Care Medicine Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College Beijing China
1 shared publication - Jian Yang
Beijing Institute of Technology
1 shared publication Jin Bian
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 19 November 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (1) , 188-198
Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
Introduction: The increasing application of immune checkpoint inhibitors (ICIs) will cause more checkpoint inhibitor‐related pneumonitis (CIP), which is a common cause of ICI‐related death. The clinical management of CIP needs further optimization.Methods: Patients who were managed at Peking Union Medical College Hospital (PUMCH) between February 2017 and December 2019 with a diagnosis of CIP were retrospectively analyzed. Clinical data including clinical manifestations, radiologic data, laboratory and bronchoscopy results, treatments, and outcomes were collected and analyzed. The Mann–Whitney test was used to compare patients with and without co‐infections.Results: In total, 48 CIP cases in 42 patients were analyzed. The median time from the first dose of ICI to the onset of CIP was 1.9 months (range: 0.1–13.7). Grade 3–4 (G3–4) accounted for 30 cases (71.4%). The most common symptoms were cough (88.1%) and dyspnea (78.6%). The median starting dose of equivalent prednisone (EP) was 55 mg (range: 30–200) for all patients. The median total duration of glucocorticosteroids (GCS) treatment was 42.5 days (range: 15−89). Three patients (7.14%) died because of infection. A higher starting dose and longer duration of GCS (≥30 mg/day; p = 0.001) were associated with opportunistic infection. Chest computed tomography (CT) showed diverse and asymmetrical lesions. Twelve patients were re‐challenged, and six patients developed recurrent CIP.Conclusions: The clinical and imaging manifestations of CIP are various, and differential diagnosis of exclusion is essential. GCS at 1–2 mg/kg is feasible to treat CIP, but the duration of GCS ≥30 mg/day should be used with caution, given the high risk of acquired infections. Re‐challenges of ICI are feasible, but the recurrence of CIP needs to be closely monitored.
- 19 November 2020
- Published by Wiley in Cancer Medicine
- Vol. 10 (1) , 188-198
Open AccessClinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
Introduction: The increasing application of immune checkpoint inhibitors (ICIs) will cause more checkpoint inhibitor‐related pneumonitis (CIP), which is a common cause of ICI‐related death. The clinical management of CIP needs further optimization.Methods: Patients who were managed at Peking Union Medical College Hospital (PUMCH) between February 2017 and December 2019 with a diagnosis of CIP were retrospectively analyzed. Clinical data including clinical manifestations, radiologic data, laboratory and bronchoscopy results, treatments, and outcomes were collected and analyzed. The Mann–Whitney test was used to compare patients with and without co‐infections.Results: In total, 48 CIP cases in 42 patients were analyzed. The median time from the first dose of ICI to the onset of CIP was 1.9 months (range: 0.1–13.7). Grade 3–4 (G3–4) accounted for 30 cases (71.4%). The most common symptoms were cough (88.1%) and dyspnea (78.6%). The median starting dose of equivalent prednisone (EP) was 55 mg (range: 30–200) for all patients. The median total duration of glucocorticosteroids (GCS) treatment was 42.5 days (range: 15−89). Three patients (7.14%) died because of infection. A higher starting dose and longer duration of GCS (≥30 mg/day; p = 0.001) were associated with opportunistic infection. Chest computed tomography (CT) showed diverse and asymmetrical lesions. Twelve patients were re‐challenged, and six patients developed recurrent CIP.Conclusions: The clinical and imaging manifestations of CIP are various, and differential diagnosis of exclusion is essential. GCS at 1–2 mg/kg is feasible to treat CIP, but the duration of GCS ≥30 mg/day should be used with caution, given the high risk of acquired infections. Re‐challenges of ICI are feasible, but the recurrence of CIP needs to be closely monitored.
- Open Access
- 1 October 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (19) , 1246
Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages.
- 1 October 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (19) , 1246
Open AccessSafety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages.
- Open Access
- 14 January 2017
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 16 (1) , 1-12
Automatic liver segmentation based on appearance and context information
Automated image segmentation has benefits for reducing clinicians’ workload, quicker diagnosis, and a standardization of the diagnosis. This study proposes an automatic liver segmentation approach based on appearance and context information. The relationship between neighboring pixels in blocks is utilized to estimate appearance information, which is used for training the first classifier and obtaining the probability distribution map. The map is used for extracting context information, along with appearance features, to train the next classifier. The prior probability distribution map is achieved after iterations and refined through an improved random walk for liver segmentation without user interaction. The proposed approach is evaluated using CT images with eight contemporary approaches, and it achieves the highest VOE, RVD, ASD, RMSD and MSD. It also achieves a high average score of 76 using the MICCAI-2007 Grand Challenge scoring system. Experimental results show that the proposed method is superior to eight other state of the art methods.
- 14 January 2017
- Published by Springer Nature in BioMedical Engineering OnLine
- Vol. 16 (1) , 1-12
Open AccessAutomatic liver segmentation based on appearance and context information
Automated image segmentation has benefits for reducing clinicians’ workload, quicker diagnosis, and a standardization of the diagnosis. This study proposes an automatic liver segmentation approach based on appearance and context information. The relationship between neighboring pixels in blocks is utilized to estimate appearance information, which is used for training the first classifier and obtaining the probability distribution map. The map is used for extracting context information, along with appearance features, to train the next classifier. The prior probability distribution map is achieved after iterations and refined through an improved random walk for liver segmentation without user interaction. The proposed approach is evaluated using CT images with eight contemporary approaches, and it achieves the highest VOE, RVD, ASD, RMSD and MSD. It also achieves a high average score of 76 using the MICCAI-2007 Grand Challenge scoring system. Experimental results show that the proposed method is superior to eight other state of the art methods.
- 1 December 2016
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 5 (6) , 509-510
Comments on “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis”
Comments on “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis”
- 1 December 2016
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 5 (6) , 509-510
Comments on “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis”
Comments on “NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis”